WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles:
Related suggestion:
'We are not in control': NZ law must prohibit foreign spyingOpen fires banned in Hawke's BayShayne Carter: ‘Art has always been completely undervalued’Trump to stand trial on 25 March in New York criminal hush money caseTrump to stand trial on 25 March in New York criminal hush money caseThe royals have historically been tightScrapping clean car discount cost $138m in fuel savings – transport officialsPakistan ex'Tenants who have pets often stay'Week in Politics: Government's year starts with a problem
3.2373s , 6491.25 kb
Copyright © 2024 Powered by Why Amylyx is pulling ALS drug Relyvrio from US market after study ,Global Gazette news portal